Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The Cyclic nucleotide-gated channel alpha-3 (CNGA3) is the pore-forming alpha subunit of the heterotetrameric cone photoreceptor CNG channel, assembling in a 3:1 stoichiometry with CNGB3 to form a functional complex essential for vertebrate phototransduction. In cone photoreceptors, it transduces light-induced decreases in cGMP levels into electrical signals by closing the channel, hyperpolarizing the membrane and reducing glutamate release. The channel conducts Na+ and Ca2+ ions in the dark when cGMP keeps it open, supporting steady depolarization. Structural features include an asymmetric selectivity filter with three glutamates, a hydrophobic cavity gate, and a putative lower gate formed by CNGB3 residues like R442, which influence ion permeation, Ca2+ block, and ligand gating. CNGA3 is regulated by phosphoinositides via N- and C-terminal domains, modulating cGMP/cAMP efficacy and adapting channel sensitivity. Pathogenic mutations in CNGA3, such as R410W or Q196L, disrupt channel function, causing achromatopsia—a congenital cone dystrophy with complete color blindness, photophobia, and nystagmus—and account for up to 95% of cases when combined with CNGB3 defects. No approved drugs directly target CNGA3, but its role in channelopathies suggests potential for gating modulators to address gain-of-function mutants that promote cone degeneration.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Cyclic nucleotide-gated channel alpha-3 (CNGA3).